Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). The target enrollment of a minimum of 300 subjects for the SER-109 safety database was reached in conjunction with a prior completed Phase 3 study, ECOSPOR lll. Seres is re

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

The microbiome has arrived as a significant area of opportunity for new treatments of infectious and chronic conditions. While the importance of the microbiome is clear, validated products remain elusive.

Seres Therapeutics: Here We Go Again

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference: Seres will participate in a pre-recorded fireside chat that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET. Morgan Stanley 19th Annual Global Healthcare Conference: Seres will participate in a fireside chat on W

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood sold over 840,000 shares of Seres Therapeutics Inc.

Cathie Wood's ARK Invest Sells Over 840,000 Shares of Seres Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a discussion at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 9:00 a.m. ET. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. Abo

Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates

Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53), which missed the estimate of ($0.37).

Recap: Seres Therapeutics Q2 Earnings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates. “We have made strong progress advancing SER-109, which we expect will become the first-ever FDA-approved microbiome therapeutic. We are nearing target enrollment i

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m. ET to discuss second quarter 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6519859. To join the live webcast, please visi

Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021

The company reported disappointing results from a phase 2b clinical study.

Why Seres Therapeutics Stock Is Crashing Today

The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) fell by over 50% pre-market. This is why it happened.

MCRB Stock Fell Over 50% Pre-Market: Why It Happened

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID numbe

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).  The study did not meet its primary endpoint of improving clinical remission rates compared to placebo.

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared to placebo. Both dosing regimens of SER-287 were generally well tolerated. Given the lack of a clinical efficacy signal identified in ECO-RESET,

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options

eXp World Holdings Inc

Ideaya Biosciences Inc

iQIYI

Mitek Systems

Moderna

Plug Power

Poshmark

Riot Blockchain

TG Therapeutics

Twist Bioscience Corp

Vuzix

These July selections are the current top positive and negative forensic stocks based on combined scores from four different forensic algorithms. The past 5 Negative Forensic portfolios have returned: Jan 2021 +16.7%, July 2020: +114.1%, Feb 2020: +64.9%, Dec 2019: +59.0%, Oct 2019: +108.2%.

Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021

Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under development for patients with recurrent C.

Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases

CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Under th

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET. During the event, Seres' management and Stephen Hanauer, M.D., Professor of Medicine at Northwestern University Feinberg School of Medicine will discuss the UC patient burden, the need for new therapeutic approach

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:00 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available ap

Seres Therapeutics to Present at JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease (GvHD). The data are being presented in

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

The FDA has signed off  Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia, and graft-versus-host disease (GvHD).

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming investor conferences: Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Tuesday, June 1, 2021 Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET on Tuesday, June 8, 2021 An audio webcast of each presentation will be available under the “Investors and News” section of

News for Seres Therapeutics Stock (MCRB)